Syros Announces Closing of Concurrent Public Offerings
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/26/2026
- Wall Street dips on hot inflation data ahead of Nvidia earnings
- Oil settles down after choppy session as investors weigh Hormuz talks
- Meta to pay up to $16.68 billion in mass social media settlement
- Anthropic agrees to $45bn cloud computing deal with Nscale - report
- Citi sees an opportunity in Oracle after ’one of the most extreme’ stock drawdowns
- Boston Scientific discloses cybersecurity incident causing global disruption
- Crude Inventory Rose 0.1 Million Barrels Last Week - EIA
- Wall Street ends higher as tech rebounds before Nvidia results
- Six Flags to move headquarters from Charlotte to Arlington, Texas
- FDA approves Revolution Medicines pancreatic cancer drug Rasonque
Syros Pharmaceuticals (SYRS) PT Lowered to $24 at Piper Jaffray
April 10, 2019 9:19 AM EDTPiper Jaffray analyst Edward Tenthoff lowered the price target on Syros Pharmaceuticals (NASDAQ: SYRS) to $24.00 (from $28.00) while maintaining a Overweight rating. Syros recently raised gross proceeds of $70 million, bringing estimated pro forma cash to ~$165 million.
Syros is developing potentially best-in-class CDK7 inhibitors.... More
